One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (ClinicalTrials.gov number, NCT00045032.)

The addition of postoperative irradiation to mastectomy and adjuvant chemotherapy reduces locoregional recurrences and prolongs survival in high-risk premenopausal women with breast cancer.

We have calculated optimal frequency scaling factors for the B3LYP/ 6-311+G(d,p) method for fundamental vibrational frequencies on the basis of a set of 125 molecules. Using the new scaling factor, the vibrational frequencies calculated with the triple-zeta basis set 6-311+G(d,p) give significantly better accuracy than those calculated with the double-zeta 6-31G(d) basis set. Scale factors were also determined for low-frequency vibrations using the molecular set of 125 molecules and for zero-point energies using a smaller set of 40 molecules. We have studied the effect on the calculated vibrational frequencies for various combinations of diffuse and polarization functions added to the triple-zeta 6-311G basis set. The 6-311+G(d,p) basis set is found to give almost converged frequencies for most molecules, and we conclude that our optimum scaling factors are valid for the basis sets 6-311G(d,p) to 6-311++G(3df,3pd). The new scale factors are 0.9679 for vibrational frequencies, 1.0100 for low-frequency vibrations, and 0.9877 for zero-point vibrational energies.

No abstract

REATMENT OF HODGKIN DISease (HD) represents one of the major medical successes of the 20th century. Fifty years ago, the typical patient survived only a few years, 1 whereas the current 5-year relative survival rate is 85%. 2 In the United States alone, approximately 120000 survivors of HD 2 are at risk for the serious late sequelae of curative therapies, including the occurrence of new primary cancers. 3,4 Second malignant neoplasms are now the leading cause of death in longterm survivors of HD, 5,6 with breast cancer representing the most frequent solid tumor among women. 7,8 Estimates of breast cancer risk appear inversely related to age at treat-Author Affiliations are listed at the end of this article.

Continuation of trastuzumab plus capecitabine showed a significant improvement in overall response and time to progression compared with capecitabine alone in women with HER-2-positive breast cancer who experienced progression during trastuzumab treatment.

No abstract

No abstract